iSpecimen (ISPC) Stock Price, News & Analysis

Company Overview

iSpecimen, Inc. is a healthcare technology company that operates an online marketplace connecting life sciences researchers with healthcare providers, biobanks, laboratories and other sources of human biospecimens. Its platform is designed to help researchers identify, request and obtain biological samples and related clinical data for use in drug development, diagnostics, biomarker research and other scientific applications.

The company’s services support the sourcing of a broad range of specimens, including blood, tissue, bodily fluids and other human-derived samples. Through its technology platform, iSpecimen helps research organizations define sample requirements, search for suitable specimens, manage orders and coordinate fulfillment with participating providers. The company serves pharmaceutical and biotechnology companies, academic and government researchers, diagnostic developers and medical device organizations.

iSpecimen was founded in 2009 and is headquartered in Lexington, Massachusetts. The company’s marketplace is intended to expand access to specimens from provider networks in the United States and other regions, while helping healthcare organizations make samples available for approved research uses. iSpecimen became a publicly traded company on the Nasdaq under the symbol ISPC in 2021.

Key Stats

• Today's Range: $0.91 to $1.02
• 50-Day Range: $0.92 to $2.38
• 52-Week Range: $0.91 to $36.32
• Volume: 47,527 shs
• Average Volume: 351,265 shs
• Market Capitalization: $2.31 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

iSpecimen Stock Analysis - MarketRank™

iSpecimen scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

iSpecimen has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

iSpecimen has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of iSpecimen is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of iSpecimen is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

iSpecimen has a P/B Ratio of 0.06. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.28% of the float of iSpecimen has been sold short.

Short Interest Ratio / Days to Cover

iSpecimen has a short interest ratio ("days to cover") of 0.27, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in iSpecimen has recently decreased by 27.06%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

iSpecimen does not currently pay a dividend.

Dividend Growth

iSpecimen does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: N/A

News Sentiment

iSpecimen has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for iSpecimen this week, compared to 1 article on an average week.

Search Interest

2 people have searched for ISPC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, iSpecimen insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.20% of the stock of iSpecimen is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

13.62% of the stock of iSpecimen is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/16/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:ISPC
• CIK: 1558569
• Web: ispecimen.com
• Phone: 781-301-6700
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($56.44)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.49 million
• Net Margins: -2,445.40%
• Pretax Margin: -2,445.61%
• Return on Equity: -524.39%
• Return on Assets: -140.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.82
• Quick Ratio: 0.82

Sales & Book Value

• Annual Sales: $1.93 million
• Price / Sales: 1.20
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $14.57 per share
• Price / Book: 0.06

Miscellaneous

• Outstanding Shares: 2,520,000
• Free Float: 2,212,000
• Market Cap: $2.31 million
• Optionable: Not Optionable
• Beta: 1.65